Cargando…
Phosphodiesterase-5 Inhibitors as Therapeutics for Cardiovascular Diseases: A Brief Review
BACKGROUND: Three selective and most used inhibitors of PDE-5-sildenafil, vardenafil and tadalafil- have been successfully used for the treatment of erectile dysfunction. Erectile dysfunction and cardiovascular diseases might be considered as two dissimilar clinical signs of the identical systemic d...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tehran University of Medical Sciences
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362213/ https://www.ncbi.nlm.nih.gov/pubmed/37484720 http://dx.doi.org/10.18502/ijph.v52i5.12704 |
_version_ | 1785076375988731904 |
---|---|
author | Corbic, Milena Sretenovic, Jasmina Zivkovic, Vladimir Jakovljevic, Vladimir Nikolic Turnic, Tamara |
author_facet | Corbic, Milena Sretenovic, Jasmina Zivkovic, Vladimir Jakovljevic, Vladimir Nikolic Turnic, Tamara |
author_sort | Corbic, Milena |
collection | PubMed |
description | BACKGROUND: Three selective and most used inhibitors of PDE-5-sildenafil, vardenafil and tadalafil- have been successfully used for the treatment of erectile dysfunction. Erectile dysfunction and cardiovascular diseases might be considered as two dissimilar clinical signs of the identical systemic disease. PDE-5 inhibitors can through different models and mechanisms induce vasodilation, decrease apoptosis and cell proliferation, and they are widely present in various tissues that make them promising targets in a range of cardiovascular diseases. METHODS: PubMed was explored to identify papers published from 1990–2019, presenting data for the most used PDE-5 inhibitors (sildenafil, tadalafil or vardenafil) in treatment of cardiovascular diseases. RESULTS: This article analyses the therapeutic potentials of PDE-5 inhibitors in cardiovascular diseases and discusses mechanisms, possible risks and limitations. Comparable to earlier studies, newer studies suggest cardioprotective effects of PDE-5 inhibitors, which include different models and mechanisms and do not indicate an increased rate of significant cardiovascular adverse reactions. Dissimilarity in the pharmacokinetics and pharmacodynamics of PDE-5 inhibitors are significant to their risk- benefit profile and clinical use. Some of the studies suggesting infarct size reduction after PDE-5 inhibition described the especially close dose-effect relation, other studies dosage adaptation in drug- drug interactions. CONCLUSION: PDE-5 inhibitors indicate the encouraging useful effects by ischemia/reperfusion injury, myocar-dial infarction, cardiac hypertrophy, cardiomyopathy and systolic and diastolic congestive heart failure. Therefore, this and similar reviews can help for additional clinical targeting in the therapy of cardiovascular diseases. |
format | Online Article Text |
id | pubmed-10362213 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Tehran University of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-103622132023-07-23 Phosphodiesterase-5 Inhibitors as Therapeutics for Cardiovascular Diseases: A Brief Review Corbic, Milena Sretenovic, Jasmina Zivkovic, Vladimir Jakovljevic, Vladimir Nikolic Turnic, Tamara Iran J Public Health Review Article BACKGROUND: Three selective and most used inhibitors of PDE-5-sildenafil, vardenafil and tadalafil- have been successfully used for the treatment of erectile dysfunction. Erectile dysfunction and cardiovascular diseases might be considered as two dissimilar clinical signs of the identical systemic disease. PDE-5 inhibitors can through different models and mechanisms induce vasodilation, decrease apoptosis and cell proliferation, and they are widely present in various tissues that make them promising targets in a range of cardiovascular diseases. METHODS: PubMed was explored to identify papers published from 1990–2019, presenting data for the most used PDE-5 inhibitors (sildenafil, tadalafil or vardenafil) in treatment of cardiovascular diseases. RESULTS: This article analyses the therapeutic potentials of PDE-5 inhibitors in cardiovascular diseases and discusses mechanisms, possible risks and limitations. Comparable to earlier studies, newer studies suggest cardioprotective effects of PDE-5 inhibitors, which include different models and mechanisms and do not indicate an increased rate of significant cardiovascular adverse reactions. Dissimilarity in the pharmacokinetics and pharmacodynamics of PDE-5 inhibitors are significant to their risk- benefit profile and clinical use. Some of the studies suggesting infarct size reduction after PDE-5 inhibition described the especially close dose-effect relation, other studies dosage adaptation in drug- drug interactions. CONCLUSION: PDE-5 inhibitors indicate the encouraging useful effects by ischemia/reperfusion injury, myocar-dial infarction, cardiac hypertrophy, cardiomyopathy and systolic and diastolic congestive heart failure. Therefore, this and similar reviews can help for additional clinical targeting in the therapy of cardiovascular diseases. Tehran University of Medical Sciences 2023-05 /pmc/articles/PMC10362213/ /pubmed/37484720 http://dx.doi.org/10.18502/ijph.v52i5.12704 Text en Copyright © 2023 Corbic et al. Published by Tehran University of Medical Sciences https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license (https://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited. |
spellingShingle | Review Article Corbic, Milena Sretenovic, Jasmina Zivkovic, Vladimir Jakovljevic, Vladimir Nikolic Turnic, Tamara Phosphodiesterase-5 Inhibitors as Therapeutics for Cardiovascular Diseases: A Brief Review |
title | Phosphodiesterase-5 Inhibitors as Therapeutics for Cardiovascular Diseases: A Brief Review |
title_full | Phosphodiesterase-5 Inhibitors as Therapeutics for Cardiovascular Diseases: A Brief Review |
title_fullStr | Phosphodiesterase-5 Inhibitors as Therapeutics for Cardiovascular Diseases: A Brief Review |
title_full_unstemmed | Phosphodiesterase-5 Inhibitors as Therapeutics for Cardiovascular Diseases: A Brief Review |
title_short | Phosphodiesterase-5 Inhibitors as Therapeutics for Cardiovascular Diseases: A Brief Review |
title_sort | phosphodiesterase-5 inhibitors as therapeutics for cardiovascular diseases: a brief review |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362213/ https://www.ncbi.nlm.nih.gov/pubmed/37484720 http://dx.doi.org/10.18502/ijph.v52i5.12704 |
work_keys_str_mv | AT corbicmilena phosphodiesterase5inhibitorsastherapeuticsforcardiovasculardiseasesabriefreview AT sretenovicjasmina phosphodiesterase5inhibitorsastherapeuticsforcardiovasculardiseasesabriefreview AT zivkovicvladimir phosphodiesterase5inhibitorsastherapeuticsforcardiovasculardiseasesabriefreview AT jakovljevicvladimir phosphodiesterase5inhibitorsastherapeuticsforcardiovasculardiseasesabriefreview AT nikolicturnictamara phosphodiesterase5inhibitorsastherapeuticsforcardiovasculardiseasesabriefreview |